Creating new types of nanoparticles for drug delivery
Expanding the design space of polyelectrolyte complex micelles
This study is exploring new tiny particles that can safely deliver medicines, like genetic treatments, in the body, and it's aimed at improving how well these treatments work for people with different health conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas at Austin NIH-funded |
| Lab location | 1 site (Austin, United States) |
| Project ID | NIH-10941677 on NIH RePORTER |
What this research studies
This research focuses on developing polyelectrolyte complex micelles (PCMs), which are specialized nanoparticles designed to deliver therapeutic agents like nucleic acids. The team will systematically investigate how different polymer structures and properties affect the micelles' ability to carry and release their payloads in the body. Using advanced imaging techniques and computational analysis, they aim to establish clear design rules that can enhance the effectiveness of these delivery systems. This work could lead to more reliable and efficient treatments for various conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who require nucleic acid therapies, such as those with genetic disorders or certain cancers.
Not a fit: Patients not requiring nucleic acid therapies or those with conditions unrelated to the delivery systems being developed may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the delivery of nucleic acid-based therapies, making treatments more effective for patients.
How similar studies have performed: Previous research has shown promise in using similar nanoparticle delivery systems, indicating potential for success in this area.
Where this research is happening
Austin, United States
- University of Texas at Austin — Austin, United States (Active)
Researchers
- Principal investigator: Marras, Alexander Edison — University of Texas at Austin
- Study coordinator: Marras, Alexander Edison
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.